Knowledge Library

Oligonucleotide Drug Discovery

Recent years have seen a huge surge of interest in oligonucleotide therapeutics, fueled by major advances in our understanding of how to make such molecules stable, selective, and efficient as drug modalities. The field is now diverse in terms of therapeutic areas being addressed, biological processes being manipulated and delivery technologies employed. In this webinar, …Read More >

Resource Type: Webinar
Resource Topic: Biochemical Assays Cell-based Assays Discovery Chemistry Hit-to-Lead in vitro biology in vivo Pharmacology Lead Optimization Oligonucleotides Safety and Early Toxicity

VIEW

Pain Discovery Assays & in vivo Studies

WuXi Discovery Services supports all of your research needs, including target discovery, in vitro and in vivo pharmacology, translational research and clinical biomarker testing, to enable drug discovery for your target compound for pain. Full-scale molecular characterizations from gene/protein expression in vitro functional assays with validation of GPCR, Kinase and ion channel targets Selectivity profiling …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Biomarkers Cell-based Assays Central Nervous System & Pain in vitro biology in vivo Pharmacology Lead Optimization Target Identification and Validation Target-Specific Assays

VIEW

OncoWuXi Newsletter: June 2022

WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform

Resource Type: Newsletter
Resource Topic: Antibodies Cell-based Assays Hit-to-Lead in vivo Pharmacology Lead Optimization Oncology Target-Specific Assays Tumor Models

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platform. Integrated Chemistry and Biology Research Platform | From Discovery to Candidate Selection and Beyond

Resource Type: Brochure
Resource Topic: Antibodies Antibody Drug Conjugate Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Biophysical Assays Candidate Selection CAR-T Cell Cardiovascular & Metabolic Diseases Cell Therapies Cell-based Assays Cells and Protein Science Central Nervous System & Pain Chemical Biology and Proteomics CRISPR/Cas9 Dermatology Discovery Chemistry DNA-Encoded Library (DEL) DRUG DISCOVERY AND INNOVATION Fragment-Based Drug Discovery Gene Manipulation Gene Therapies High-throughput screening (HTS) Hit Finding Hit-to-Lead Immunology in silico services in vitro biology in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Liver Diseases Mass Spectrometry-based Assays Metabolic Diseases NASH Oligonucleotides Oncology Oncolytic Viruses Ophthalmology Phenotypic Assays Quantum Mechanics Rare Diseases Respiratory Diseases Safety and Early Toxicity Screening Libraries Screening Services Small Molecules Structural Biology Target Identification and Validation Target-Specific Assays Targeted Protein Degradation TECHNOLOGY PLATFORMS THERAPEUTIC AREAS THERAPEUTIC MODALITIES Tumor Models

VIEW

Bone metastasis platform to evaluate prophylaxis and treatment

Resource Type: Presentation
Resource Topic: in vivo Pharmacology Lead Optimization Oncology Small Molecules Target Identification and Validation

VIEW

Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase

Structure-based design was utilized to optimize 6,6-diaryl substituted dihydropyrone and hydroxylactam to obtain inhibitors of lactate dehydrogenase (LDH) with low nanomolar biochemical and single-digit micromolar cellular potencies. Surprisingly the replacement of a phenyl with a pyridyl moiety in the chemical structure revealed a new binding mode for the inhibitors with subtle conformational change of the …Read More >

Resource Type: Publication
Resource Topic: Chemical Biology and Proteomics Discovery Chemistry Hit-to-Lead Lead Optimization Oncology Small Molecules

VIEW

Brain metastasis mouse models for the evaluation of multikinase inhibitors on ROS1-fusion-positive lung cancer

Lung cancer is the leading cause of cancer-related death worldwide.  Nearly 80% of lung cancers are non-small cell lung cancer (NSCLC) and 60% of them are diagnosed at the metastatic stage. Brain metastases affect more than 20% of NSCLC patients with poor prognosis and disabling symptoms. However, few therapies have been approved for the treatment …Read More >

Resource Type: Poster
Resource Topic: in vivo Pharmacology Lead Optimization Oncology Small Molecules Tumor Models

VIEW

Developing a panel of orthotopic syngeneic tumor models for IO drug discovery

The efficacy of immuno-oncology therapies needs to be evaluated in animal models with functional immune systems. Syngeneic tumor models are established by inoculating mouse cancer cell lines into immunocompetent mice with the same genetic background. The host mice have complete immune activity and show histocompatibility with homograft tumor tissues, which can maximize the simulation of …Read More >

Resource Type: Poster
Resource Topic: Antibodies in vivo Pharmacology Lead Optimization Oncology Target Identification and Validation Tumor Models

VIEW

Development of an integrated in vitro and in vivo OVA-specific system for cancer vaccine discovery

We have established an advanced and integrated in vitro and in vivo platform for various types of cancer vaccines, including peptide vaccines, mRNA vaccines, DC vaccines and more. Ovalbumin (OVA) is a key model antigen which has been widely used in vaccination experiments. Here we established an OVA overexpressed system based on different types of …Read More >

Resource Type: Latest Science Poster
Resource Topic: Biomarkers Cell-based Assays Immunology in vitro biology Lead Optimization Oncology Target Identification and Validation Target-Specific Assays Tumor Models

VIEW


Resource Topics